NO20050528L - Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft - Google Patents
Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreftInfo
- Publication number
- NO20050528L NO20050528L NO20050528A NO20050528A NO20050528L NO 20050528 L NO20050528 L NO 20050528L NO 20050528 A NO20050528 A NO 20050528A NO 20050528 A NO20050528 A NO 20050528A NO 20050528 L NO20050528 L NO 20050528L
- Authority
- NO
- Norway
- Prior art keywords
- combination
- cancer
- treatment
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title 1
- 108091008605 VEGF receptors Proteins 0.000 title 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000005865 ionizing radiation Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0218526.2A GB0218526D0 (en) | 2002-08-09 | 2002-08-09 | Combination therapy |
| PCT/GB2003/003390 WO2004014426A1 (en) | 2002-08-09 | 2003-08-05 | Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050528L true NO20050528L (no) | 2005-05-03 |
Family
ID=9942013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050528A NO20050528L (no) | 2002-08-09 | 2005-01-31 | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050245549A1 (enExample) |
| EP (1) | EP1534338A1 (enExample) |
| JP (1) | JP2006500346A (enExample) |
| KR (1) | KR20050059060A (enExample) |
| CN (1) | CN100556456C (enExample) |
| BR (1) | BR0313117A (enExample) |
| CA (1) | CA2495489A1 (enExample) |
| GB (1) | GB0218526D0 (enExample) |
| IL (1) | IL166625A0 (enExample) |
| MX (1) | MXPA05001457A (enExample) |
| NO (1) | NO20050528L (enExample) |
| NZ (1) | NZ537754A (enExample) |
| WO (1) | WO2004014426A1 (enExample) |
| ZA (1) | ZA200501061B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1244647E (pt) * | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| IL151626A0 (en) | 2000-04-07 | 2003-04-10 | Astrazeneca Ab | Quinazoline compounds |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| EP2292615A1 (en) | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Quinazoline compounds |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| DE602004032310D1 (de) * | 2003-02-13 | 2011-06-01 | Astrazeneca Ab | Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| JP2007526886A (ja) * | 2003-07-10 | 2007-09-20 | アストラゼネカ アクチボラグ | 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用 |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| AU2006236940A1 (en) * | 2005-04-14 | 2006-10-26 | Wyeth | Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients |
| WO2007014335A2 (en) * | 2005-07-27 | 2007-02-01 | The University Of Texas System | Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| CA2631764A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| CA2663599A1 (en) | 2006-09-18 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Method for treating cancer harboring egfr mutations |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
| SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| GB201516905D0 (en) * | 2015-09-24 | 2015-11-11 | Stratified Medical Ltd | Treatment of Neurodegenerative diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| AU2002223684A1 (en) * | 2000-11-22 | 2002-06-03 | Novartis Pharma Gmbh | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| CA2482591A1 (en) * | 2002-04-16 | 2003-10-30 | Astrazeneca Ab | Combination therapy for the treatment of cancer |
| AU2003249000B2 (en) * | 2002-08-09 | 2007-04-05 | Astrazeneca Ab | Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| DE602004032310D1 (de) * | 2003-02-13 | 2011-06-01 | Astrazeneca Ab | Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 |
| JP2007526886A (ja) * | 2003-07-10 | 2007-09-20 | アストラゼネカ アクチボラグ | 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用 |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| CA2631764A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
-
2002
- 2002-08-09 GB GBGB0218526.2A patent/GB0218526D0/en not_active Ceased
-
2003
- 2003-08-05 JP JP2004527018A patent/JP2006500346A/ja active Pending
- 2003-08-05 WO PCT/GB2003/003390 patent/WO2004014426A1/en not_active Ceased
- 2003-08-05 BR BR0313117-3A patent/BR0313117A/pt not_active IP Right Cessation
- 2003-08-05 KR KR1020057002187A patent/KR20050059060A/ko not_active Ceased
- 2003-08-05 US US10/523,838 patent/US20050245549A1/en not_active Abandoned
- 2003-08-05 EP EP03784248A patent/EP1534338A1/en not_active Withdrawn
- 2003-08-05 NZ NZ537754A patent/NZ537754A/en not_active IP Right Cessation
- 2003-08-05 CA CA002495489A patent/CA2495489A1/en not_active Abandoned
- 2003-08-05 CN CNB038191105A patent/CN100556456C/zh not_active Expired - Fee Related
- 2003-08-05 MX MXPA05001457A patent/MXPA05001457A/es active IP Right Grant
-
2005
- 2005-01-31 NO NO20050528A patent/NO20050528L/no not_active Application Discontinuation
- 2005-02-01 IL IL16662505A patent/IL166625A0/xx unknown
- 2005-02-04 ZA ZA200501061A patent/ZA200501061B/en unknown
-
2009
- 2009-07-13 US US12/501,593 patent/US20100130493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1674938A (zh) | 2005-09-28 |
| JP2006500346A (ja) | 2006-01-05 |
| IL166625A0 (en) | 2006-01-15 |
| MXPA05001457A (es) | 2005-06-06 |
| CN100556456C (zh) | 2009-11-04 |
| NZ537754A (en) | 2008-02-29 |
| GB0218526D0 (en) | 2002-09-18 |
| CA2495489A1 (en) | 2004-02-19 |
| US20050245549A1 (en) | 2005-11-03 |
| BR0313117A (pt) | 2005-07-05 |
| EP1534338A1 (en) | 2005-06-01 |
| AU2003252976A1 (en) | 2004-02-25 |
| WO2004014426A1 (en) | 2004-02-19 |
| ZA200501061B (en) | 2007-01-31 |
| US20100130493A1 (en) | 2010-05-27 |
| KR20050059060A (ko) | 2005-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| NO20060307L (no) | Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet | |
| NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
| NO20072167L (no) | Kombinasjon omfattende ZD6474 og et antiandrogen | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
| NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| NO20050450L (no) | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft | |
| DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
| CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| NO20066054L (no) | behandling med cisplatin og en EGFR-inhibitor | |
| EA200501166A1 (ru) | Составы и способы лечения тромбоцитемии | |
| NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
| NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
| NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
| NO20066080L (no) | Behandling med irinotecan (CPT-11) og en AGFR-inhibitor | |
| NO20064753L (no) | Kombinasjonsterapi | |
| NO20064755L (no) | Kombinasjonsterapi | |
| NO20064754L (no) | Kombinasjonsterapi | |
| ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |